Combination of cytokine-induced killer and dendritic cells pulsed with antigenic alpha-1,3-galactosyl epitope-enhanced lymphoma cell membrane for effective B-cell lymphoma immunotherapy

doi:10.1016/j.jcyt.2015.09.012

CORC > 兰州大学 > 兰州大学 > 第二临床医学院 > 期刊论文

	Combination of cytokine-induced killer and dendritic cells pulsed with antigenic alpha-1,3-galactosyl epitope-enhanced lymphoma cell membrane for effective B-cell lymphoma immunotherapy
	Qiu, Y; Yun, MM; Dong, XB; Xu, MB; Zhao, RD; Han, X; Zhou, EX; Yun, FY; Su, WY; Liu, CX
刊名	CYTOTHERAPY
	2016-01
卷号	18 期号:1 页码:91-98
关键词	alpha-1,3-galactosyl epitope cytokine-induced killer dendritic cell epitope immunotherapy refractory lymphoma
ISSN号	1465-3249
DOI	10.1016/j.jcyt.2015.09.012
文献子类	Article
英文摘要	Background aims. Refractory B-cell lymphomas are difficult to successfully treat with current chemotherapeutic regimens; however, immunotherapy may be an effective form of treatment for these patients. Methods. Fourteen refractory lymphoma patients (age, 29-74 y) were enrolled in the trial. alpha-1,3-galactosyl (alpha-Gal) epitopes were synthesized on lymphoma cell membranes with the use of bovine recombinant alpha-1,3-galactosyltransferase (alpha-GT) and neuraminidase to enhance tumor immunogenicity. Subsequent incubation of processed cell membranes with autologous dendritic cells (DCs) in the presence of human serum containing abundant natural anti alpha-Gal immunoglobulin G led to the effective phagocytosis of tumor membranes by DCs. The pulsed DCs and autologous cytokine-induced killer cells were then co-cultured to promote maximum cytotoxicity to lymphoma cells and were infused back into the donor lymphoma patients. Therapeutic responses were assessed by clinical observation, laboratory tests and a computed tomography scan at 6 months after treatment. Results. Complete and partial remission occurred in four and three patients, respectively. The disease status remained unchanged in five patients, and disease progression was observed in two patients. No serious side effects or autoimmune diseases were observed in any participants. Serum lactate dehydrogenase and beta-macroglobulin decreased in 11 and 14 patients, respectively. All patients showed robust systemic cytotoxicity in response to tumor lysate as measured by interferon-gamma expression in peripheral blood mononuclear cells after treatment (P < 0.001). The number of peripheral immune effector cells (CD3(+)/CD4(+), CD8(+)/CD28(+) and CD16(+)/CD56(+) cells) increased significantly (P < 0.05) 3 months after treatment. Conclusions. Lymphoma cell specific alpha-Gal immunotherapy is safe, effective and has great potential for the treatment of refractory B-cell lymphoma.
学科主题	Cell Biology ; Biotechnology & Applied Microbiology ; Hematology ; Research & Experimental Medicine
出版地	OXFORD
资助项目	国家自然科学基金项目
项目编号	National Natural Science Foundation of China [81360354] ; Inner Mongolia Key Grants [KJT10JHG, KJT13SF02]
语种	英语
WOS记录号	WOS:000368467700009
资助机构	NSFC
内容类型	期刊论文
源URL	[http://ir.lzu.edu.cn/handle/262010/179416]
专题	第二临床医学院_期刊论文
通讯作者	Yun, S (reprint author), Affiliated Hosp Inner Mongolia Med Univ, Stem Cell Ctr, Dept Oncol, 1 Tongdao Beijie, Hohhot 010050, Peoples R China.
推荐引用方式 GB/T 7714	Qiu, Y,Yun, MM,Dong, XB,et al. Combination of cytokine-induced killer and dendritic cells pulsed with antigenic alpha-1,3-galactosyl epitope-enhanced lymphoma cell membrane for effective B-cell lymphoma immunotherapy[J]. CYTOTHERAPY,2016,18(1):91-98.
APA	Qiu, Y.,Yun, MM.,Dong, XB.,Xu, MB.,Zhao, RD.,...&Yun, S .(2016).Combination of cytokine-induced killer and dendritic cells pulsed with antigenic alpha-1,3-galactosyl epitope-enhanced lymphoma cell membrane for effective B-cell lymphoma immunotherapy.CYTOTHERAPY,18(1),91-98.
MLA	Qiu, Y,et al."Combination of cytokine-induced killer and dendritic cells pulsed with antigenic alpha-1,3-galactosyl epitope-enhanced lymphoma cell membrane for effective B-cell lymphoma immunotherapy".CYTOTHERAPY 18.1(2016):91-98.